References
Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 2023;842:191–206.
Williams IS, McVey A, Perera S, O’Brien JS, Kostos L, Chen K, et al. Modern paradigms for prostate cancer detection and management. Med J Aust. 2022;2178:424–33.
Petrelli F, Dottorini L, De Stefani A, Vavassori I, Luciani A. Localized prostate cancer in older patients: radical prostatectomy or radiotherapy versus observation. J Geriatr Oncol. 2024;156:101792.
Kupelian PA, Mahadevan A, Reddy CA, Reuther AM, Klein EA. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology. 2006;683:593–8.
Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010;287:1106–11.
Agarwal PK, Sadetsky N, Konety BR, Resnick MI, Carroll PR. Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer. 2008;1122:307–14.
Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, et al. Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: a network meta-analysis of randomized trials. J Clin Oncol. 2020;3826:3024–31.
Matei DV, Ferro M, Jereczek-Fossa BA, Renne G, Crisan N, Bottero D, et al. Salvage radical prostatectomy after external beam radiation therapy: a systematic review of current approaches. Urol Int. 2015;944:373–82.
Zargar H, Lamb AD, Rocco B, Porpiglia F, Liatsikos E, Davis J, et al. Salvage robotic prostatectomy for radio recurrent prostate cancer: technical challenges and outcome analysis. Minerva Urol Nefrol. 2017;691:26–37.
Golbari NM, Katz AE. Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: a literature review. Curr Urol Rep. 2017;188:63.
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU Guidelines on Prostate Cancer. Edn. presented at the EAU Annual Congress Paris April 2024. ISBN 978-94-92671-23-3. https://uroweb.org/guidelines/prostate-cancer
Felício de Campos E, Xavier CB, Queiroz MM, Firmino Lima Júnior N, Ilario EN, Coelho RF, et al. Cardiovascular and thromboembolic events in patients with localized prostate cancer receiving intensified neoadjuvant androgen deprivation: a systematic review and meta-analysis. Clin Genitourin Cancer. 2024;223:102088.
Guo RQ, Guo XX, Li YM, Bie ZX, Li B, Li XG. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis. Int J Clin Oncol. 2021;263:461–84.
Kayano PP, Klotz L. Current evidence for focal therapy and partial gland ablation for organ-confined prostate cancer: systematic review of literature published in the last 2 years. Curr Opin Urol. 2021;311:49–57.
Yaxley WJ, Gianduzzo T, Kua B, Oxford R, Yaxley JW. Focal therapy for prostate cancer with irreversible electroporation: Oncological and functional results of a single institution study. Investig Clin Urol. 2022;633:285–93.
Faiella E, Santucci D, Vertulli D, Vergantino E, Vaccarino F, Perillo G, et al. Irreversible Electroporation (IRE) for Prostate Cancer (PCa) treatment: The State of the Art. J Pers Med. 2024;14:137.
Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality-clinical implications. Technol Cancer Res Treat. 2007;61:37–48.
Onik G, Rubinsky B. Irreversible electroporation: first patient experience focal therapy of prostate cancer. In: Rubinsky B, editor. Irreversible electroporation. Berlin, Heidelberg: Springer Berlin Heidelberg; 2010. p. 235–47.
Guenther E, Klein N, Zapf S, Weil S, Schlosser C, Rubinsky B, et al. Prostate cancer treatment with Irreversible Electroporation (IRE): safety, efficacy and clinical experience in 471 treatments. PLoS ONE. 2019;144:e0215093.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;67:e1000100.
Musshafen LA, Tyrone RS, Abdelaziz A, Sims-Gomillia CE, Pongetti LS, Teng F, et al. Associations between sleep and academic performance in US adolescents: a systematic review and meta-analysis. Sleep Med. 2021;83:71–82.
Yilmaz M, Karaaslan M, Şirin ME, Polat ME, Aybal H, Toprak T, et al. Intraoperative workload of the surgeon in robot-assisted radical prostatectomy: a systematic review. J Robot Surg. 2024;181:289.
Geboers B, Scheltema MJ, Blazevski A, Katelaris A, Doan P, Ali I, et al. Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer. BJU Int. 2023;131:14–22.
Gielchinsky I, Lev-Cohain N. Focal irreversible electroporation for localized prostate cancer - oncological and safety outcomes using mpMRI and transperineal biopsy follow-up. Res Rep Urol. 2023;15:27–35.
Scheltema MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, et al. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. BJU Int. 2017;120:51–58.
Blazevski A, Geboers B, Scheltema MJ, Gondoputro W, Doan P, Katelaris A, et al. Salvage irreversible electroporation for radio-recurrent prostate cancer - the prospective FIRE trial. BJU Int. 2023;131:23–31.
Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;566:899–905.
Davalos RV, Mir IL, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;332:223–31.
Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel image-guided cancer therapy. Gut Liver. 2010;4:S99–s104.
Prabhakar P, Avudaiappan AP, Sandman M, Eldefrawy A, Caso J, Narayanan G, et al. Irreversible electroporation as a focal therapy for localized prostate cancer: a systematic review. Indian J Urol. 2024;401:6–16.
Onik G, Mikus P, Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat. 2007;64:295–300.
Zhang K, Teoh J, Zhu G, Ng CF, Suberville M, Laguna P, et al. Irreversible electroporation for the focal treatment of prostate cancer: a systematic review. World J Mens Health. 2024. https://doi.org/10.5534/wjmh.240012 [Epub ahead of print].
Miñana López B, Andrés Boville G, Barbas Bernardos G, Ancizu Marckert X, Torres Roca M, Labairu Huerta L, et al. Focal therapy of prostate cancer index lesion with irreversible electroporation. a prospective study with a median follow-up of 3 years. J Urol. 2023;2091:261–70.
Valerio M, Dickinson L, Ali A, Ramachadran N, Donaldson I, McCartan N, et al. Nanoknife electroporation ablation trial: a prospective development study investigating focal irreversible electroporation for localized prostate cancer. J Urol. 2017;1973:647–54.
